Evommune EVO756 Phase 2b misses primary endpoint in CSU; development halted for that indication

Evommune, Inc.

Phase 2b trial of EVO756 in 160 CSU patients did not meet primary endpoint of UAS7 change at 12 weeks at any dose.
Company will cease EVO756 development for CSU but will continue evaluation in atopic dermatitis and migraine.
Top-line Phase 2b data for EVO756 in atopic dermatitis expected Q3 2026; migraine trial screening initiated.
Cash position supports anticipated operations through 2028; EVO301 Phase 2b for AD in planning.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.